
    
      LB80380, an oral prodrug, is a promising candidate nucleotide analogue with antiviral
      activity against wild-type HBV. LB80380 is undergoing clinical development by LG Life
      Sciences for use in the treatment of chronic HBV infection.

      In this study, the treatment period is 48-week with 24-week of follow-up period.
    
  